Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

(This Feb. 5 story has been refiled to correct the name of the unit to biosciences and diagnostic solutions, from life sciences, in the headline and paragraphs 1 and 4) (Reuters) - Becton Dickinson ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

Wells Fargo lowered the firm’s price target on Becton Dickinson (BDX) to $270 from $275 and keeps an Overweight rating on the shares. The firm ...

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $280.00.